Institute for Applied Cancer Science
The cancer genomics and molecular profiling group aims to advance the understanding of changes in the activity of human genes that contribute at the molecular level to the tumor progression and resistance to drugs with an ultimate goal of improving clinical outcomes. The toolbox includes digital gene expression profiling by state-of-the-art techniques NanoString and RNAseq, as well as mutation analysis by whole exome and whole genome next generation sequencing (the image is a visualization of millions of sequence reads produced in parallel), microarrays, and multicolor FISH. The IACS is capable of performing molecular characterization of thousands of samples per year, in addition to retaining the necessary flexibility to rapidly address actual challenges of the institute’s drug validation pipeline.
The cancer genomics and molecular profiling group is led by Alexei Protopopov, Ph.D.